This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
VBI Vaccines Inc.
Drug Names(s): GBM Vaccine (VBI), GBM Cancer Immunotherapy Program, VBI1901, VBI 1901
Description: VBI Vaccines is developing a vaccine candidate for the treatment of glioblastoma multiforme (GBM), using its eVLP Platform technology. The vaccine has been designed to direct an immune response against glycoprotein B and pp65, two cytomegalovirus (CMV) antigens. The vaccine candidate includes an adjuvant that mobilizes dendritic function and enhances Th1-type immunity.
SciVac and VBI
In October 2015, VBI Vaccines and SciVac announced that they have entered into an agreement and plan of merger (the Agreement) under which SciVac has agreed to acquire VBI to form a commercial-stage company with a licensed hepatitis B (HBV) vaccine and a pipeline of preventative and therapeutic vaccine candidates.
In May 2016, VBI Vaccines and SciVac announced the completion of their previously announced merger transaction, whereby SciVac acquired VBI. VBI survives the merger as a wholly owned subsidiary of SciVac. Upon completion of the merger, SciVac changed its name to VBI Vaccines Inc.
Additional information available to subscribers only: